Protective efficacy of recombinant modified vaccinia virus Ankara delivering Middle East respiratory syndrome coronavirus spike glycoprotein

Journal of Virology

Volumn 89, Issue 16, 2015, Pages 8651-8656

  Volz, Asisa ^a   Kupke, Alexandra ^b   Song, Fei ^a   Jany, Sylvia ^a   Fux, Robert ^a   Shams Eldin, Hosam ^b   Schmidt, Jörg ^b   Becker, Christin ^c   Eickmann, Markus ^b   Becker, Stephan ^b   Sutter, Gerd ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELL RECEPTOR; CORONAVIRUS SPIKE GLYCOPROTEIN; DIPEPTIDYL PEPTIDASE 4 RECEPTOR; NEUTRALIZING ANTIBODY; RECOMBINANT MODIFIED VACCINIA VIRUS ANKARA VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CORONAVIRUS INFECTION; DRUG EFFICACY; DRUG SAFETY; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS INFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRAL GENE DELIVERY SYSTEM; ANIMAL; BAGG ALBINO MOUSE; CORONAVIRUS INFECTIONS; GENETICS; IMMUNOLOGY; METABOLISM; PRECLINICAL STUDY; PROCEDURES; VACCINIA VIRUS;

CORONAVIRUS; MUS; VACCINIA VIRUS ANKARA;

ANIMALS; ANTIBODIES, NEUTRALIZING; CD8-POSITIVE T-LYMPHOCYTES; CORONAVIRUS INFECTIONS; DRUG EVALUATION, PRECLINICAL; MICE; MICE, INBRED BALB C; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; SPIKE GLYCOPROTEIN, CORONAVIRUS; VACCINIA VIRUS; VIRAL VACCINES;

EID: 84938151524     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00614-15     Document Type: Article

References (31)

1. Al-Tawfiq JA, Memish ZA. 2014. Middle East respiratory syndrome coronavirus: epidemiology and disease control measures. Infect Drug Resist 7:281-287.
2. Al-Tawfiq JA, Memish ZA. 2014. Middle East respiratory syndrome coronavirus: transmission and phylogenetic evolution. Trends Microbiol 22: 573-579. http://dx.doi.org/10.1016/j.tim.2014.08.001.
3. Coleman CM, Frieman MB. 2014. Coronaviruses: important emerging human pathogens. J Virol 88:5209-5212. http://dx.doi.org/10.1128/JVI.03488-13.
4. Raj VS, Mou H, Smits SL, Dekkers DHW, Muller MA, Dijkman R, Muth D, Demmers JAA, Zaki A, Fouchier RAM, Thiel V, Drosten C, Rottier PJM, Osterhaus ADME, Bosch BJ, Haagmans BL. 2013. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 495:251-254. http://dx.doi.org/10.1038/nature12005.
5. Agrawal AS, Garron T, Tao X, Peng B-H, Wakamiya M, Chan T-S, Couch RB, Tseng C-TK. 2015. Generation of transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease. J Virol 89:3659-3670. http://dx.doi.org/10.1128/JVI.03427-14.
6. Zhao J, Li K, Wohlford-Lenane C, Agnihothram SS, Fett C, Zhao J, Gale MJ, Baric RS, Enjuanes L, Gallagher T, McCray PB, Perlman S. 2014. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci U S A 111:4970-4975. http://dx.doi.org/10.1073/pnas.1323279111.
7. Hotez PJ, Bottazzi ME, Tseng C-TK, Zhan B, Lustigman S, Du L, Jiang S. 2014. Calling for rapid development of a safe and effective MERS vaccine. Microbes Infect 16:529-531. http://dx.doi.org/10.1016/j.micinf.2014.05.002.
8. Coleman CM, Liu YV, Mu H, Taylor JK, Massare M, Flyer DC, Glenn GM, Smith GE, Frieman MB. 2014. Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine 32:3169-3174. http://dx.doi.org/10.1016/j.vaccine.2014.04.016.
9. Du L, Zhao G, Kou Z, Ma C, Sun S, Poon VKM, Lu L, Wang L, Debnath AK, Zheng B-J, Zhou Y, Jiang S. 2013. Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development. J Virol 87:9939-9942. http://dx.doi.org/10.1128/JVI.01048-13.
10. Kim E, Okada K, Kenniston T, Raj VS, AlHajri MM, Farag EABA, Al Hajri F, Osterhaus ADME, Haagmans BL, Gambotto A. 2014. Immunogenicity of an adenoviral-based Middle East respiratory syndrome coronavirus vaccine in BALB/c mice. Vaccine 32:5975-5982. http://dx.doi.org/10.1016/j.vaccine.2014.08.058.
11. Ma C, Wang L, Tao X, Zhang N, Yang Y, Tseng C-TK, Li F, Zhou Y, Jiang S, Du L. 2014. Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments-the importance of immunofocusing in subunit vaccine design. Vaccine 32:6170-6176. http://dx.doi.org/10.1016/j.vaccine.2014.08.086.
12. Mou H, Raj VS, van Kuppeveld FJM, Rottier PJM, Haagmans BL, Bosch BJ. 2013. The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies. J Virol 87: 9379-9383. http://dx.doi.org/10.1128/JVI.01277-13.
13. Song F, Fux R, Provacia LB, Volz A, Eickmann M, Becker S, Osterhaus ADME, Haagmans BL, Sutter G. 2013. Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies. J Virol 87:11950-11954. http://dx.doi.org/10.1128/JVI.01672-13.
14. Altenburg AF, Kreijtz JHCM, de Vries RD, Song F, Fux R, Rimmelzwaan GF, Sutter G, Volz A. 2014. Modified vaccinia virus Ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases. Viruses 6:2735-2761. http://dx.doi.org/10.3390/v6072735.
15. Gilbert SC. 2013. Clinical development of modified vaccinia virus Ankara vaccines. Vaccine 31:4241-4246. http://dx.doi.org/10.1016/j.vaccine.2013.03.020.
16. Gómez CE, Perdiguero B, García-Arriaza J, Esteban M. 2013. Clinical applications of attenuated MVA poxvirus strain. Expert Rev Vaccines 12: 1395-1416. http://dx.doi.org/10.1586/14760584.2013.845531.
17. Kremer M, Volz A, Kreijtz JCM, Fux R, Lehmann M, Sutter G. 2012. Easy and efficient protocols for working with recombinant vaccinia virus MVA, p 59-92. In Isaacs SN (ed), Vaccinia virus and poxvirology, vol 890. Humana Press, Totowa, NJ.
18. European Medicines Agency. 2010. Guideline on quality, non-clinical and clinical aspects of live recombinant viral vectored vaccines. EMA/ CHMP/VWP/141697/2009. European Medicines Agency, London, United Kingdom.
19. Frey SE, Newman FK, Kennedy JS, Sobek V, Ennis FA, Hill H, Yan LK, Chaplin P, Vollmar J, Chaitman BR, Belshe RB. 2007. Clinical and immunologic responses to multiple doses of IMVAMUNE® (modified vaccinia Ankara) followed by Dryvax challenge. Vaccine 25:8562-8573. http://dx.doi.org/10.1016/j.vaccine.2007.10.017.
20. Frey SE, Winokur PL, Hill H, Goll JB, Chaplin P, Belshe RB. 2014. Phase II randomized, double-blinded comparison of a single high dose (5×10(8) TCID50) of modified vaccinia Ankara compared to a standard dose (1×10(8) TCID50) in healthy vaccinia-naïve individuals. Vaccine 32:2732-2739. http://dx.doi.org/10.1016/j.vaccine.2014.02.043.
21. Greenberg RN, Overton ET, Haas DW, Frank I, Goldman M, von Krempelhuber A, Virgin G, Bädeker N, Vollmar J, Chaplin P. 2013. Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects. J Infect Dis 207:749-758. http://dx.doi.org/10.1093/infdis/jis753.
22. Walsh SR, Wilck MB, Dominguez DJ, Zablowsky E, Bajimaya S, Gagne LS, Verrill KA, Kleinjan JA, Patel A, Zhang Y, Hill H, Acharyya A, Fisher DC, Antin JH, Seaman MS, Dolin R, Baden LR. 2013. Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial. J Infect Dis 207: 1888-1897. http://dx.doi.org/10.1093/infdis/jit105.
23. European Medicines Agency. 2013. Imvamex: modifiziertes Vacciniavirus Ankara lebend. EMA/490157/2013. European Medicines Agency, London, United Kingdom.
24. Kreijtz JHCM, Goeijenbier M, Moesker FM, van den Dries L, Goeijenbier S, De Gruyter HLM, Lehmann MH, de Mutsert G, van de Vijver DAMC, Volz A, Fouchier RAM, van Gorp ECM, Rimmelzwaan GF, Sutter G, Osterhaus ADME. 2014. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial. Lancet Infect Dis 14: 1196-1207. http://dx.doi.org/10.1016/S1473-3099(14)70963-6.
25. + T cells in wild-type and type I interferon receptordeficient mice correlates with protection after low-dose emergency immunization with modified vaccinia virus Ankara. J Virol 88:10946-10957. http://dx.doi.org/10.1128/JVI.00945-14.
26. Bisht H, Roberts A, Vogel L, Bukreyev A, Collins PL, Murphy BR, Subbarao K, Moss B. 2004. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci U S A 101:6641-6646. http://dx.doi.org/10.1073/pnas.0401939101.
27. Jaume M, Yip MS, Cheung CY, Leung HL, Li PH, Kien F, Dutry I, Callendret B, Escriou N, Altmeyer R, Nal B, Daëron M, Bruzzone R, Peiris JSM. 2011. Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH-and cysteine protease-independent FcγR pathway. J Virol 85:10582-10597. http://dx.doi.org/10.1128/JVI.00671-11.
28. Jaume MYM, Kam YW, Cheung CY, Kien F, Roberts A, Li PH, Dutry I, Escriou N, Daeron M, Bruzzone R, Subbarao K, Peiris JS, Nal B, Altmeyer R. 2012. SARS CoV subunit vaccine: antibody-mediated neutralisation and enhancement. Hong Kong Med J 18(Suppl 2):31-36.
29. Roberts A, Lamirande EW, Vogel L, Jackson JP, Paddock CD, Guarner J, Zaki SR, Sheahan T, Baric R, Subbarao K. 2008. Animal models and vaccines for SARS-CoV infection. Virus Res 133:20-32. http://dx.doi.org/10.1016/j.virusres.2007.03.025.
30. + T cell determinants to enable rational design and characterization of smallpox vaccines. J Exp Med 201:95-104. http://dx.doi.org/10.1084/jem.20041912.
31. Corman VMEI, Bleicker T, Zaki A, Landt O, Eschbach-Bludau M, van Boheemen S, Gopal R, Ballhause M, Bestebroer TM, Muth D, Müller MA, Drexler JF, Zambon M, Osterhaus AD, Fouchier RM, Drosten C. 2012. Detection of a novel human coronavirus by real-time reversetranscription polymerase chain reaction. Euro Surveill 17:pii=20285. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20285.